Leerink Partners Initiates Coverage on AbCellera Biologics with "Outperform" Rating and $5.00 Price Target

Leerink Partners initiates coverage on AbCellera Biologics (ABCL) with an "Outperform" rating and a new price target of $5.00. Analyst Faisal Khurshid forecasts potential upside for ABCL shares. The average one-year price target from 7 analysts is $8.43, with an average brokerage recommendation of 1.9, indicating "Outperform" status. The estimated GF Value for ABCL in one year is $1.61, suggesting a downside of 57.63% from the current price.

Leerink Partners has initiated coverage on AbCellera Biologics (NASDAQ:ABCL) with an "Outperform" rating and a new price target of $5.00. Analyst Faisal Khurshid forecasts potential upside for ABCL shares. The average one-year price target from 7 analysts is $8.43, with an average brokerage recommendation of 1.9, indicating "Outperform" status. The estimated GF Value for ABCL in one year is $1.61, suggesting a downside of 57.63% from the current price.

The stock has shown strong momentum recently, gaining nearly 11% in the past week and trading close to its 52-week high of $4.08 [2]. AbCellera Biologics builds an engine for antibody drug discovery and development, with its preclinical products ABCL635 for metabolic and endocrine conditions, and ABCL575 for atopic dermatitis. The company has shifted its focus from being primarily an antibody discovery platform to developing its own internal pipeline of therapeutic candidates [2].

Leerink Partners highlighted two upcoming programs: ABCL575, an OX40L antagonist targeting atopic dermatitis, and ABCL635, an NK3R antagonist for vasomotor symptoms. Both candidates are scheduled to enter Phase 1 clinical trials in the third quarter of 2025, with data expected in 2026 [2]. The research firm noted that ABCL575’s extended half-life positions it favorably compared to competing OX40L monoclonal antibodies, while ABCL635 targets the vasomotor symptoms market, which Leerink believes is currently underappreciated by investors [2].

AbCellera Biologics reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.02 [1]. The company had a negative net margin of 737.56% and a negative return on equity of 15.98%. The business had revenue of $4.24 million during the quarter, compared to analyst estimates of $7.12 million [1].

Several institutional investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in AbCellera Biologics by 248.2% in the first quarter [1]. Institutional investors own 61.42% of the company's stock [1].

The company's strategic focus on clinical trials and innovation remains a central theme as it moves forward. AbCellera Biologics has a market cap of $1.16 billion, a PE ratio of -6.95, and a beta of 0.62. The stock has a one-year low of $1.89 and a one-year high of $4.13. The business has a 50-day moving average of $2.69 and a 200-day moving average of $2.73 [1].

References:
[1] https://www.marketbeat.com/instant-alerts/abcellera-biologics-nasdaqabcl-coverage-initiated-by-analysts-at-leerink-partners-2025-07-07/
[2] https://in.investing.com/news/analyst-ratings/leerink-partners-assumes-coverage-on-abcellera-stock-with-outperform-rating-93CH-4901826